Building materials firm Lords Group buys rival CMO in rescue deal
London-listed firm Lords said it acquired the 'trade and assets' of CMO for around £1.8 million as part of a pre-pack administration.
The deal will secure the future of around 120 workers at Plymouth-based CMO, who will join the wider Lords group.
CMO, which was founded in 2008 as Construction Materials Online, sells more than 140,000 products to trade professionals and households through a raft of specialist superstore-branded websites.The company was listed on London's AIM junior stock market until February, when it delisted in order to help preserve funds.
The firms highlighted that the deal will not include the Tiles business previously owned by CMO.
Dean Murray, chief executive of CMO, said: 'The acquisition marks a new and exciting chapter for CMO.
'We have built a strong, digitally-led business over the past 15 years, and in Lords, we have found a partner that not only understands our model but shares our ambition.
'I am incredibly proud of what the CMO team has achieved and excited about what is next.'
Shanker Patel, chief executive of Lords, said: 'We are delighted to welcome CMO into the Lords family.
'CMO brings a well-established digital platform, strong customer reach, and a specialist product-led approach that complements our own.
'This partnership allows us to blend traditional merchanting strengths with cutting-edge digital capabilities.
'We are also mindful of the impact of the pre-pack administration process on affected parties and are committed to conducting the transition with respect.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
35 minutes ago
- Reuters
Eyekandy Launches Sales Ambassador, World's First Digital Human Super-Salesperson for Every Point of Purchase
LONDON, United Kingdom, June 11, 2025 (EZ Newswire) -- Eyekandy, opens new tab, a global leader in immersive retail commerce, today announced the launch of Sales Ambassador™, the world's first digital human super-salesperson created to transform the shopping experience at every point of purchase. Sales Ambassador is an advanced AI-powered digital human who provides real-time, human-like product guidance for shoppers online, in-store, and on social channels. This isn't just another text based chatbot—the solution delivers visual human-like, always-on support, personalized recommendations, combined with a unique use of augmented reality to showcase products for shoppers, enabling brands and retailers to offer consistent, expert assistance to every customer, anytime and anywhere. With the rapid adoption of AI in retail, Eyekandy's Sales Ambassador addresses two critical challenges facing the industry: driving sales and reducing servicing costs. The digital human never sleeps, never takes breaks, and communicates fluently in more than 20 languages. It analyzes individual shopper needs and delivers tailored product recommendations, helping customers make confident purchase decisions and reducing costly returns. Sales Ambassador integrates effortlessly into existing retail infrastructure, offering plug-and-play deployment for brands and retailers seeking to enhance customer engagement without increasing headcount. 'Sales Ambassador is built to perform better than the best sales rep—24/7,' said Joe Golden, product director of Eyekandy. 'Our technology guides shoppers across web, mobile, social, and even in-store kiosks, driving conversions and providing real-time support at every stage of the buying journey.' The global immersive technology market was valued at $44 billion in 2024 and is projected to reach $184 billion by 2030, growing at a CAGR of over 26%. AI for sales and marketing is anticipated to hit $58 billion by 2025, with more than 70% of U.S. retail executives planning to increase their investment in AI over the next year. Eyekandy's Sales Ambassador is positioned to capitalize on this growth, offering a scalable solution for brands seeking to optimize sales and operational efficiency. 'Imagine deploying your most persuasive and knowledgeable salesperson to every product page, every store aisle, and every shopper's pocket,' added Golden. 'Sales Ambassador does not just sell—it delivers a consistent, personalized experience that builds brand trust and drives measurable results.' Retailers and brands ready to enhance customer confidence, reduce returns, and unlock new sales growth can visit opens new tab to learn more and request a live demonstration, opens new tab. About Eyekandy Eyekandy is a leading provider of immersive commerce solutions, specializing in advanced AI and augmented reality to enhance the shopping experience for consumers and brands. Established in 2016, Eyekandy serves more than 100 retailers and brands across 36 countries, reaching over half a billion unique visitors annually. The company has received multiple innovation awards for its dedication to creativity and excellence in retail technology. For more information, visit Media Contact Angela Platts letstalk@ ### SOURCE: Eyekandy Copyright 2025 EZ Newswire See release on EZ Newswire
Daily Mail
an hour ago
- Daily Mail
Firm linked to Baroness Bra 'must pay back £122m for faulty PPE': Government suing over Covid contract 'initiated' by Tory peer
A firm linked to Michelle Mone must repay £122million for allegedly breaching a Covid PPE contract, a court heard yesterday. The bra tycoon had recommended PPE Medpro, which went on to provide 25 million 'faulty' surgical gowns. The consortium, led by the Tory peer's husband Doug Barrowman, was awarded contracts by the former Conservative administration during the pandemic. PPE Medpro is now being sued by the Department of Health and Social Care (DHSC), with Government lawyers claiming the gowns couldn't be used because they were not sterile. Baroness Mone and the firm both deny any wrongdoing. The Government is seeking to recover the costs of the contract, plus an additional £8,648,691 for transporting and storing the items. PPE Medpro said it 'categorically denies' breaching the contract, with its lawyers claiming the company has been 'singled out for unfair treatment'. Opening the trial, Paul Stanley KC, for the DHSC, said: 'This case is simply about whether 25 million surgical gowns provided by PPE Medpro were faulty. It is, in short, a technical case about detailed legal and industry standards that apply to sterile gowns.' Mr Stanley said in written submissions the 'initial contact with Medpro came through Baroness Mone', with contract discussions then going through one of the firm's directors, Anthony Page. Baroness Mone remained 'active throughout' negotiations, he said, with the peer stating Mr Barrowman had 'years of experience in manufacturing, procurement and management of supply chains'. But he said Baroness Mone's communications were not part of this case, which was 'simply about compliance'. He added: 'The department does not allege anything improper happened, and we are not concerned with any profits made by anybody.' In court documents from May this year, the DHSC said the gowns were delivered to the UK in 72 lots between August and October 2020, with almost £122million paid to PPE Medpro between July and August that year. The department rejected the gowns in December 2020 and told the firm it would have to repay the money, but this has not happened and the gowns remain in storage. Mr Stanley said 99.9999 per cent of the gowns should have been sterile under the terms of the contract. The DHSC claims the deal also specified PPE Medpro had to sterilise them using a 'validated process', attested by CE marking, which indicates a product has met certain medical standards. He said 'none of those things happened', and that of 140 gowns tested for sterility, 103 failed. He added that the DHSC 'was entitled to reject the gowns, or is entitled to damages, which amount to the full price and storage costs'. Charles Samek KC, for PPE Medpro, said the 'only plausible reason' for the gowns becoming contaminated was due to 'the transport and storage conditions or events to which the gowns were subject' after delivery. He said testing was done several months after the gowns were rejected, and that the samples were not 'representative of the whole population'. Mr Samek described the DHSC's claim as 'contrived and opportunistic', with PPE Medpro 'made the fall guy for a catalogue of failures... and uncontrolled buying spree with taxpayers' money'. Neither Baroness Mone nor Mr Barrowman is due to give evidence during the five-week trial. A PPE Medpro spokesman said it 'categorically denies breaching its obligations' and will 'robustly defend' the claim.
Daily Mail
an hour ago
- Daily Mail
Experts cast doubt on Reeves' plan to make her sums add up by saving billions through ‘technical efficiency gains', slashing admin spending and clamping down on tax
Experts have cast doubt on the Chancellor's plan to make her sums add up by saving billions through 'technical efficiency gains', slashing admin spending and clamping down on tax. The Treasury said it planned to make more use of artificial intelligence, reforming the workforce – including through job cuts – and selling off its London property portfolio. The plans are forecast to save £13.8 billion a year by 2028/29 – including £9 billion a year from the health and social care budget alone. At the same time, a drive to recover more owed taxes is predicted to deliver a £7.5 billion annual gain by 2029/30. And government department administration costs will be culled by 11 per cent by the time of the next election, the Treasury projects – with another huge cut pencilled in for 2026 which will take the savings to 16 per cent, or £2.2 billion. Raoul Ruparel, a former Downing Street adviser to Theresa May, said the latter were 'pretty brutal real-terms cuts across the board'. 'Traditionally, these sorts of cuts are very hard to deliver,' said Mr Ruparel, who is director of the Boston Consulting Group Centre for Growth. The plans for efficiency savings rely heavily on making the National Health Service more productive – that is, doing more with less. They assume annual productivity growth of 2 per cent a year in the NHS, which the Treasury admits would mark a 'substantial increase' on improvements achieved in past years. The productivity plan 'will deliver efficiencies across all healthcare services, primarily through the combined impact of operational and clinical improvements, technology and digital transformation and workforce initiatives', the Treasury said. They will include reducing the use of agency staff and levels of sickness absence. The Government also plans to relocate more civil servants out of London, cutting the number by 12,000 by 2030. But at the same time, its ambition to bring in more unpaid taxes will involve hiring more people – with 5,500 compliance and 2,400 debt management staff expected to be brought in. The closure of 11 central London offices will save £94 million a year by 2032 and the disposal of properties no longer needed will bring in £1 billion, the Government said. Julian Jessop, economics fellow at the Institute of Economic Affairs think-tank, said: 'There is huge scope to boost productivity and make efficiency savings in the public sector. 'It is much less obvious that this Government will be the one to do it.' Also among the expected savings is the claim that the Ministry of Housing will use AI to speed up routine tasks such as checking errors and note taking. 'This will reduce demands on staff time by an estimated 500,000 hours per year,' the Treasury said. Ms Reeves also announced that she will tear up Treasury rules designed to safeguard value for money in order to pour money into infrastructure projects in the Midlands and the North, where Labour is under threat from Reform. Regional mayors have railed for years at the Treasury's so-called 'Green Book' rules which direct investment to areas where it will produce the most economic benefit. Under the new system, the Treasury will limit the use of 'benefit-cost reviews' which have been blamed for halting investment in the North. The new proposals will mean that even projects where the costs outweigh the benefits may not 'automatically constitute poor value for money'.
